One lens, two problems solved: Drug-eluting IOL shows promise for cataract and glaucoma patients

A novel intraocular lens that doubles as a glaucoma drug delivery system is turning heads in ophthalmology. The bimatoprost drug pad-IOL (BIM-IOL) — which slowly releases glaucoma medication from two tiny pads embedded in the lens — proved noninferior to standard timolol eye drops for reducing intraocular pressure (IOP) over 12 months, while simultaneously correcting vision after cataract removal. Results were presented at the American Academy of Ophthalmology annual meeting.

The device is designed to tackle two longstanding challenges: the poor adherence associated with daily eye drops (nonadherence rates run 30–80%) and the relatively low adoption of minimally invasive glaucoma surgery (~40%). By folding IOP management into routine cataract surgery, the BIM-IOL could meaningfully simplify care for patients managing both conditions.

By the Numbers:

• 34–42% reduction in IOP at 8 a.m. across all three study groups at 12 months
• 75% of higher-dose BIM-IOL patients achieved 20/20 or better vision
• 100% of patients achieved at least 20/32 vision
• Each lens pad contains 39 µg of bimatoprost, designed to release continuously over 3 years
• Two phase III trials are now underway

Why it matters: If phase III results hold up, the BIM-IOL could offer a one-and-done surgical solution for the millions of patients managing both cataracts and glaucoma — eliminating the daily drop burden and improving long-term outcomes.